

Fenretinide

Catalog No: tcsc0789

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Formula:

65646-68-6

C₂₆H₃₃NO₂

Pathway: Metabolic Enzyme/Protease;Autophagy

Target:

RAR/RXR;Autophagy

Purity / Grade:

>98%

Solubility:

Copyright 2021 Taiclone Biotech Corp.



DMSO : ≥ 130 mg/mL (332.01 mM)

Alternative Names:

4-HPR

Observed Molecular Weight:

391.55

Product Description

Fenretinide is a synthetic retinoid deriverative, binding to the retinoic acid receptors (**RAR**) at concentrations necessary to induce cell death.

In Vitro: Fenretinide exerts not just acute but also long term antitumor activity in selected T-ALL cell lines. Fenretinide inhibits DES activity in CCRF-CEM leukemia cells in a dose and time dependent manner, leading to a concomitant increase of the endogenous cellular dhCer content. Fenretinide (3 μ M)-induced dhCer accumulation in both CCRF-CEM and Jurkat cells^[1]. Ceramide inhibition with fenretinide protects insulin signaling. Fenretinide prevents lipid-induced reductions in insulin-stimulated glucose uptake^[2]. Fenretinide inhibits OVCAR-5 cell proliferation and viability at concentrations higher than 1 microM, with 70-90% growth inhibition at 10 microM. Fenretinide (1 microM) significantly inhibits OVCAR-5 invasion after 3 days preincubation. Endothelial cells treated with 1 microM 4-HPR fails to form tubes, but forms small cellular aggregates^[4].

In Vivo: Fenretinide (10 mg/kg, i.p.) selectively inhibits ceramide accumulation HFD-fed male C57Bl/6 mice. Fenretinide treatment improves glucose tolerance and insulin sensitivity as determined by both glucose and insulin tolerance tests^[2]. Addition of 25 mg/kg ketoconazole to Fenretinide in NOD/SCID mice increased 4-HPR plasma levels^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.